

Solid Tumors

Investigating side effects of a new medicine (migoprotafib) and whether it can be tolerated by people

RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors

Trial Status
Completed

Trial Runs In
1 Countries

Trial Identifier
NCT04252339 REFMAL 678
GO43242

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This clinical trial was done to study a new medicine (migoprotafib) that blocks (inhibits) the activity of a protein (SHP) in the body. Migoprotafib, belonging to the “SHP2 inhibitor” class of medicines, may prove beneficial for multiple cancer types that grow using the RAS/ MAPK signaling pathway. This was a Phase 1, open-label, dose escalation and expansion study of migoprotafib, carried out in the USA. This study investigated side effects to find out if migoprotafib can be tolerated by people.

Genentech, Inc. (A part of F. Hoffmann-La Roche Ltd., Switzerland) Sponsor	Phase 1 Phase
--	-------------------------

NCT04252339 REFMAL 678 GO43242
Trial Identifiers

Eligibility Criteria:

Gender All	Age ≥18 Years	Healthy Volunteers No
----------------------	-------------------------	---------------------------------
